JP Morgan Chase’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
JP Morgan Chase's DNLI Position: Q3 2026 in Review
JP Morgan Chase increased its Denali Therapeutics (DNLI) stake by 1.6% in Q3 2026, buying an estimated $106K and bringing the position to 291,531 shares worth $6.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3287.
JP Morgan Chase first reported a position in DNLI in Q1 2018 and has held it in 35 quarters since. The position peaked at $27.7M in Q4 2020. 287 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.
- JP Morgan Chase held 291,531 shares of Denali Therapeutics worth $6.22M as of Q3 2026.
- JP Morgan Chase bought 4,512 Denali Therapeutics shares in Q3 2026, an estimated $106K.
- Denali Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #3287 holding.
- JP Morgan Chase first reported a position in Denali Therapeutics in Q1 2018 and has held it in 35 quarters since.
- JP Morgan Chase's Denali Therapeutics position peaked at $27.7M in Q4 2020.
- 287 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.